$ACHN Recent News Stocks trim Ukraine-inspired
Post# of 74551
Posted On: 08/16/2014 12:33:36 PM
$ACHN Recent News
Stocks trim Ukraine-inspired fall, post weekly gain 4:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
10 Analyst Stocks to Buy Under $10 With Massive Upside Calls 9:47 a.m. Today - 247WallSt.com
Biotech Leader Gilead Sciences Scores Sovaldi Win 5:10 p.m. Aug. 15, 2014 - Investors Business Daily
Markets Close The Week On Negative Note As Ukraine Worries Mount 4:01 p.m. Aug. 15, 2014 - benzinga.com
U.S. Stocks Turn Lower; Dillard's Shares Slide On Downbeat Earnings 12:23 p.m. Aug. 15, 2014 - benzinga.com
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod 11:23 a.m. Aug. 15, 2014 - Investors Business Daily
ACH-3102 + Sovaldi = 100% 11:03 a.m. Aug. 15, 2014 - Seeking Alpha
Markets Gain; J.C. Penney Posts Narrower-Than-Expected Q2 Loss 10:23 a.m. Aug. 15, 2014 - benzinga.com
Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today 10:05 a.m. Aug. 15, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:24 a.m. Aug. 15, 2014 - benzinga.com
Morning Market Movers 8:40 a.m. Aug. 15, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More 7:40 a.m. Aug. 15, 2014 - 247WallSt.com
Cramer's Mad Money - One Of The Highest Quality Companies In The World (8/14/14) 5:39 a.m. Aug. 15, 2014 - Seeking Alpha
Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog 9:10 a.m. Aug. 11, 2014 - Zacks.com
Benzinga's Top Upgrades 7:54 a.m. Aug. 11, 2014 - benzinga.com
Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight 7:19 a.m. Aug. 11, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:05 a.m. Aug. 11, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More 7:00 a.m. Aug. 11, 2014 - 247WallSt.com
10-Q: ACHILLION PHARMACEUTICALS INC 4:04 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline 8:39 a.m. July 3, 2014 - benzinga.com
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly 2:49 p.m. June 27, 2014 - benzinga.com
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
7:00 a.m. Aug. 15, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 4:06 p.m. Aug. 7, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion 5:50 a.m. July 7, 2014 - PR Newswire - PRF
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
Stocks trim Ukraine-inspired fall, post weekly gain 4:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
10 Analyst Stocks to Buy Under $10 With Massive Upside Calls 9:47 a.m. Today - 247WallSt.com
Biotech Leader Gilead Sciences Scores Sovaldi Win 5:10 p.m. Aug. 15, 2014 - Investors Business Daily
Markets Close The Week On Negative Note As Ukraine Worries Mount 4:01 p.m. Aug. 15, 2014 - benzinga.com
U.S. Stocks Turn Lower; Dillard's Shares Slide On Downbeat Earnings 12:23 p.m. Aug. 15, 2014 - benzinga.com
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod 11:23 a.m. Aug. 15, 2014 - Investors Business Daily
ACH-3102 + Sovaldi = 100% 11:03 a.m. Aug. 15, 2014 - Seeking Alpha
Markets Gain; J.C. Penney Posts Narrower-Than-Expected Q2 Loss 10:23 a.m. Aug. 15, 2014 - benzinga.com
Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today 10:05 a.m. Aug. 15, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:24 a.m. Aug. 15, 2014 - benzinga.com
Morning Market Movers 8:40 a.m. Aug. 15, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More 7:40 a.m. Aug. 15, 2014 - 247WallSt.com
Cramer's Mad Money - One Of The Highest Quality Companies In The World (8/14/14) 5:39 a.m. Aug. 15, 2014 - Seeking Alpha
Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog 9:10 a.m. Aug. 11, 2014 - Zacks.com
Benzinga's Top Upgrades 7:54 a.m. Aug. 11, 2014 - benzinga.com
Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight 7:19 a.m. Aug. 11, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:05 a.m. Aug. 11, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More 7:00 a.m. Aug. 11, 2014 - 247WallSt.com
10-Q: ACHILLION PHARMACEUTICALS INC 4:04 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline 8:39 a.m. July 3, 2014 - benzinga.com
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly 2:49 p.m. June 27, 2014 - benzinga.com
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
7:00 a.m. Aug. 15, 2014 - GlobeNewswire Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 4:06 p.m. Aug. 7, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion 5:50 a.m. July 7, 2014 - PR Newswire - PRF
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
(0)
(0)